Vor Biopharma, Inc. (VOR)

Vor Biopharma's stock experienced fluctuations over the past six months. July 2025 saw a nearly 20% increase due to promising clinical trial results. August 2025, HC Wainwright & Co. reiterated a "Buy" rating. October 2025, Baird upgraded the stock to "Outperform," and HC Wainwright & Co. maintained its "Buy" rating. November 2025, Vor Biopharma announced a proposed public offering of $100 million of common stock, priced at $10.00 per share. December 2025, JP Morgan initiated coverage with an "Overweight" rating, and insider buying was reported. As of January 9, 2026, the share price was $13.52, a 56.53% decline from January 10, 2025. On January 12, 2026, the stock price gained 4.66%, rising to $14.15.

Specific demand seasonality for Vor Biopharma's individual products is not detailed. The biotechnology market generally experiences challenges in the summer months due to regulatory delays and a lack of catalysts, with a rebound typically occurring in the fall and towards the year-end. December is often a strong month for biotech stocks, while March and November tend to show underperformance.

Vor Biopharma, Inc. is a clinical-stage cell and genome engineering therapy company focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer patients, particularly those with hematological malignancies. The company's pipeline includes Tremtelectogene empogeditemcel (trem-cel) for AML and myelodysplastic syndrome, VCAR33 for relapsed or refractory AML, a Trem-cel+VCAR33 treatment system for high-risk AML patients, a CD33-CLL1 treatment system for AML, VADC45 targeting various diseases, and Telitacicept for autoimmune diseases.

Vor Biopharma, Inc. is headquartered in Cambridge, Massachusetts, United States, with offices at 100 Cambridgepark Drive, Suite 101, Cambridge, MA 02140, and 500 Boylston Street, Suite 1350, Boston, Massachusetts, 02116. The company has an exclusive license agreement with RemeGen Co for global rights (excluding China, Hong Kong, Macau, and Taiwan) to develop and commercialize telitacicept.

Vor Biopharma's brand reputation has been influenced by positive research updates, media coverage, speculation about partnerships, and interest from institutional investors. Insider buying, regulatory approvals, and funding injections have also contributed positively. However, a negative net income for Q1 2025 and a significant decline in share price have negatively impacted its reputation.

Vor Biopharma Inc. has 72 institutional owners holding 4,555,727 shares, with major shareholders including Susquehanna International Group, Llp and RA Capital Management, L.p.. RA Capital Management, L.P. is the largest individual shareholder, owning 51.92% of the company. Reid Hoffman holds 31% of common stock, and FMR LLC holds about 5.1%. The general public holds approximately 21% ownership.